The Great European Biopharma Bottleneck: Capital Starved and Talent Stifled
European biopharma is a maddening paradox. It has the academic firepower to generate groundbreaking discoveries but lacks the financial machinery to turn them into therapies. This is not a new problem, and it’s not a small one either. Yet every time I see another promising European biotech sell out